August 3, 2010Open Access
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Structured PICO
Does Troponin I evaluation identify trastuzumab-treated patients at risk for cardiotoxicity and lack of recovery from cardiac dysfunction?
P
Population
Trastuzumab-treated patients
I
Intervention
Troponin I (TNI) evaluation
O
Outcome
Cardiotoxicity and recovery from cardiac dysfunction despite HF therapysurrogate
Troponin I positivity identifies trastuzumab-treated patients at high risk for irreversible cardiotoxicity, highlighting its prognostic value in cardio-oncology.
Abstract
TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.